Arvinas (ARVN)
Develops PROTAC degraders around VEPPANU and clinical oncology, neurology, and neuromuscular programs.
$8.13
vs last close−0.38 (−4.42%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 85.82% | 56.12M shares | |
|---|---|---|---|
| 206 holders · as of Jun 30, 2026 | |||
| Insiders | 2.19% | 1.43M shares | |
| 14 holders · as of Jun 26, 2026 | |||
| Other | 11.99% | 7.84M shares | |
| remainder | |||
65.39M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
206 holders · 56.12M shares · 36 new positions · 116 increased · 51 reduced · 42 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 7.61M | 11.64% | +811.5K | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 4.12M | 6.31% | +233.8K | Aug 13, 2026 |
| D. E. Shaw & Co., Inc. | 3.50M | 5.35% | −143.4K | Aug 14, 2026 |
| Pfizer Inc | 3.46M | 5.29% | 0 | Aug 13, 2026 |
| Armistice Capital, LLC | 2.80M | 4.28% | +818.0K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 2.71M | 4.15% | +24.8K | Aug 13, 2026 |
| Two Sigma Investments, LP | 2.57M | 3.94% | +741.3K | Aug 14, 2026 |
| State Street Corp | 2.20M | 3.36% | +368.4K | Aug 7, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 7.90% | 5.42M | 13G | Apr 17, 2025 |
| Vanguard Portfolio Management | 6.12% | 3.92M | 13G | Apr 28, 2026 |
| D. E. Shaw & Co., L.P. | 5.30% | 3.41M | 13G | Nov 14, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 24, 2026 | Andrew Saikofficer: Chief Financial Officer | Sale | 5,696 | $8.16 | 187,432 |
| Jun 17, 2026 | Angela M. Cacaceofficer: Chief Scientific Officer | Sale | 2,576 | $7.60 | 180,390 |
| May 21, 2026 | Randy Teeldirector, officer: President and CEO | Sale | 2,209 | $9.04 | 285,009 |
| May 11, 2026 | Randy Teeldirector, officer: President and CEO | Sale | 9,657 | $9.94 | 287,218 |
| May 11, 2026 | Noah Berkowitzofficer: Chief Medical Officer | Sale | 11,108 | $9.94 | 191,395 |
| May 11, 2026 | Angela M. Cacaceofficer: Chief Scientific Officer | Sale | 9,657 | $9.94 | 182,966 |
| May 11, 2026 | David K. Loomisofficer: VP, Chief Accounting Officer | Sale | 1,919 | $9.94 | 40,193 |
| May 11, 2026 | Andrew Saikofficer: Chief Financial Officer | Sale | 11,139 | $9.94 | 193,128 |
| Mar 18, 2026 | Noah Berkowitzofficer: Chief Medical Officer | Sale | 6,435 | $11.10 | 202,503 |
| Mar 6, 2026 | Briggs Morrisondirector | Purchase | 20,000 | $13.40 | 96,021 |
House and Senate disclosures
Not reported.